Roche Glycart AG
https://www.roche.ch/en/sites/schlieren
8952 Schlieren, Wagistrasse 10
+41 43 215 10 00
The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.
Roche Glycart AG
Wagistrasse 10
8952 Schlieren
2822 Ergebnisse für "lung" unter Roche Glycart AG
Lung Cancer
... responsibility for access to or use of this website, nor for any content therein. Lung Cancer Lung cancer is the ... settings. From studying the biology of lung cancer cells in the lab to leading clinical trials testing ... Lung Cancer ... https://medically.roche.com/hu/en/oncology/diseases/ lung-cancer.html ... Lung Cancer ...
Lung Cancer
... responsibility for access to or use of this website, nor for any content therein. Lung Cancer Lung cancer is the ... settings. From studying the biology of lung cancer cells in the lab to leading clinical trials testing ... Lung Cancer ... https://medically.roche.com/global/en/oncology/diseases/ lung-cancer.html ... Lung Cancer ...
University Hospital Zurich, Research and Education Office
https://www.usz.ch/forschung/Seiten/default.aspx
8091 Zürich, Rämistrasse 100
The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.
University Hospital Zurich, Research and Education Office
Rämistrasse 100
8091 Zürich
469 Ergebnisse für "lung" unter University Hospital Zurich, Research and Education Office
Lung emphysema (smoker's lung) – University Hospital Zurich
... once this function has been activated. Page Content The lung emphysema is an irreversible ... advanced lung emphysema are active or former smokers. The consumption of marijuana also heavily increases ... Lung emphysema (smoker's lung) – University Hospital Zurich ... http://www.en.thorax.usz.ch/expert-knowledge/smokers- lung/Pages/default.aspx ... Lung emphysema (smoker's lung) – University Hospital Zurich ...
Lung emphysema (smoker's lung) – University Hospital Zurich
... once this function has been activated. Page Content The lung emphysema is an irreversible ... advanced lung emphysema are active or former smokers. The consumption of marijuana also heavily increases ... Lung emphysema (smoker's lung) – University Hospital Zurich ... http://www.en.thorax.usz.ch/expert-knowledge/smokers- lung/pages/default.aspx ... Lung emphysema (smoker's lung) – University Hospital Zurich ...
University of Zurich
https://www.campus-schlieren.uzh.ch/en.html
8952 Schlieren, Wagistrasse 12
The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.
University of Zurich
Wagistrasse 12
8952 Schlieren
480 Ergebnisse für "lung" unter University of Zurich
Evolution of lung and kidney allograft function in patients receivi...
... of long-term survivors after lung transplantation, some of them receiving kidney transplants. Little ... is known about the outcomes of kidney and lung allograft function following kidney after lung ... Evolution of lung and kidney allograft function in patients receiving kidney after lung ... Evolution of lung and kidney allograft function in patients receiving kidney after lung ... Evolution of lung and kidney allograft function in patients receiving kidney after lung ...
Immunosuppression and lung cancer of donor origin after bilateral l...
... understood. Here we describe a patient who received a bilateral lung transplantation for end-stage 'Usual ... Interstitial Pneumonia' (UIP) resulting in idiopathic lung fibrosis. The recipient presented with a non-small ... Immunosuppression and lung cancer of donor origin after bilateral lung transplantation - Zurich ... Immunosuppression and lung cancer of donor origin after bilateral lung transplantation - Zurich ... Immunosuppression and lung cancer of donor origin after bilateral lung transplantation - Zurich ...
Somagenetix
https://www.wysszurich.ch/projects/somagenetix
8952 Schlieren, Wagistrasse 23
Gene therapy solutions for patients with severe inherited diseases.
Somagenetix
Wagistrasse 23
8952 Schlieren
1141 Ergebnisse für "lung" unter Somagenetix
Lung function, sociodemographic characteristics, and psychological ...
... well as physical and sociodemographic conditions ( lung function, bronchiolitis obliterans syndrome ... , working status, and parenting). Chronic stress after a lung transplant was significantly lower than in a ... Lung function, sociodemographic characteristics, and psychological reaction to transplant ... Lung function, sociodemographic characteristics, and psychological reaction to transplant ... Lung function, sociodemographic characteristics, and psychological reaction to transplant ...
UZH - Epidemiology, Biostatistics and Prevention Institute - Natura...
... Archive Work & Health Natural history of lung cancer in Switzerland and cost-effectiveness of low ... -dose computed tomography International studies suggest that early lung cancer screening with low-dose ... UZH - Epidemiology, Biostatistics and Prevention Institute - Natural history of lung cancer in ... UZH - Epidemiology, Biostatistics and Prevention Institute - Natural history of lung cancer in ... UZH - Epidemiology, Biostatistics and Prevention Institute - Natural history of lung cancer in ...
ETH Entrepreneurship
https://ethz.ch/en/industry/entrepreneurship.html
8952 Schlieren, Wagistrasse 18
Excellence in entrepreneurship at ETH Zurich is driven by world-class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions.
ETH Entrepreneurship
Wagistrasse 18
8952 Schlieren
56 Ergebnisse für "lung" unter ETH Entrepreneurship
Development and Application of Ambient Mass Spectrometry for Diagno...
... Organisational unit Funding 149617 - Phenotyping Lung Diseases and Monitoring of Drugs via Mass Spectral ... Funding 149617 - Phenotyping Lung Diseases and Monitoring of Drugs via Mass Spectral Fingerprinting of ...
On-line Breath Metabolomics with Ambient High-Resolution Mass Spect...
... . Funding 609691 - Analytical Chemistry Instrumentation Development. (EC) 149617 - Phenotyping Lung Diseases ... - Phenotyping Lung Diseases and Monitoring of Drugs via Mass Spectral Fingerprinting of Exhaled Breath (SNF ...
CSL Vifor
https://www.csl.com/we-are-csl/our-businesses-and-products/csl-vifor
8952 Schlieren, Zürcherstrasse 39D
+41 58 851 80 00
Pioneer in iron-based therapies, CSL Vifor is a global leader in iron deficiency and iron deficiency anaemia therapies, with a history dating back to 1872, when pharmacist Caspar Friedrich Hausmann opened a pharmacy in St. Gallen, Switzerland. Since then, we have proven our ability to identify and serve therapeutic areas and patients with significant unmet medical need. Building on our heritage and expertise in iron deficiency therapy, and together with our joint company Vifor Fresenius Medical Care Renal Pharma, today we have a strong and rapidly growing presence in nephrology, and we are committed to launching the next generation of therapies to truly address the full spectrum of kidney disease.
CSL Vifor
Zürcherstrasse 39D
8952 Schlieren
13 Ergebnisse für "lung" unter CSL Vifor
CY2018_Seqirus_UK.pdf
... to the Patient Organisations listed below. Patient Organisation Purpose of Grant Amount British Lung ... Organisations listed below. Patient Organisation Purpose of Grant Amount British Lung Foundation Support for ... to the Patient Organisations listed below. Patient Organisation Purpose of Grant Amount British Lung ... Organisations listed below. Patient Organisation Purpose of Grant Amount British Lung Foundation Support for ...
Relationships with Patient Organizations
... Purpose of Grant Amount Age UK Corporate donation 71,617.55 GBP The Asthma UK and British Lung Foundation ... Purpose of Grant Amount Age UK Corporate donation 71,617.55 GBP The Asthma UK and British Lung Foundation ...
Topadur Pharma AG
8952 Schlieren, Grabenstrasse 11a
A team dedicated to develop innovative speciality medication for the treatment of severe wound-healing problems enabling significant improvements of patients quality of life. TOPADUR’s lead R&D programs are local active, highly potent, dual mode of action drugs. TOPADUR’s unique development candidates #3;work on validated drug targets resulting in higher than average clinical success chances.
Topadur Pharma AG
Grabenstrasse 11a
8952 Schlieren
17 Ergebnisse für "lung" unter Topadur Pharma AG
contact
... cosmetics Oncology Lung Fibrosis Contact info@topadur.com +41 44 755 44 66 Topadur Pharma AG Grabenstrasse ... cosmetics Oncology Lung Fibrosis Contact info@topadur.com +41 44 755 44 66 Topadur Pharma AG Grabenstrasse ...
Topadur Pharma
... studies in lung fibrosis. Pulmonary fibrosis is a chronic and usually fatal disease characterized by ... scarring (fibrosis) of the lung tissue resulting in a loss of respiratory function. IPF affects 3 million ... / University of Zurich has been awarded a 605K CHF Innosuisse grant to support proof-of-concept studies in lung ... the lung tissue resulting in a loss of respiratory function. IPF affects 3 million people worldwide ...
NEXUS Personalized Health Technologies
8952 Schlieren, Wagistrasse 18
+41 44 632 21 61
stekhoven@nexus.ethz.ch
NEXUS Personalized Health Technologies is an ETH Technology Platform created to enable and accelerate the execution of translational research projects by providing key technological resources, tools and collaboration opportunities for the personalized health research community. NEXUS is built around two interdisciplinary technology units that are staffed with professional scientists: Theragnostics Discovery and Clinical Bioinformatics.
NEXUS Personalized Health Technologies
Wagistrasse 18
8952 Schlieren
1 Ergebnisse für "lung" unter NEXUS Personalized Health Technologies
NEXUS User Day 2019 – NEXUS Personalized Health Technologies | ETH ...
... Riegler & Tijmen Booij Resistance mechanisms in non-small cell lung cancer patients upon immunotherapy ... Automation Platform Eva Riegler & Tijmen Booij 13:30-14:00 Resistance mechanisms in non-small cell lung ...
InSphero AG
8952 Schlieren, Wagistrasse 27
+41 44 515049-0
info@insphero.com
InSphero is a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. The company currently counts all of the top ten global pharmaceutical and cosmetics companies as customers and is helping them to implement its patented microtissue technology in their development work-flow.
InSphero AG
Wagistrasse 27
8952 Schlieren
16 Ergebnisse für "lung" unter InSphero AG
... Tumor Microtissue Models -HUVEC +HUVEC -HUVEC +HUVEC -HUVEC +HUVEC Lung A549 ✔ ✔ ✔ ✔ ✔ ✔ ✔ Colo699 ... Tumor Microtissue Models -HUVEC +HUVEC -HUVEC +HUVEC -HUVEC +HUVEC Lung A549 ✔ ✔ ✔ ✔ ✔ ✔ ✔ Colo699 ...
DISCO Pharmaceuticals Swiss GmbH
8952 Schlieren, Wagistrasse 25
Disco Pharmaceuticals is a young ETH spin-off company based in Zurich/Switzerland and Cologne/Germany. We leverage a novel mass spectrometric technology to investigate processes that are fundamental to cancer biology. We combine methodologies in cell biology, biochemistry, mass spectrometry with computational tools to identify proteins selectively expressed on cancer cells. Our ultimate goal is to develop innovative therapies for cancers with high unmet clinical need.
DISCO Pharmaceuticals Swiss GmbH
Wagistrasse 25
8952 Schlieren
4 Ergebnisse für "lung" unter DISCO Pharmaceuticals Swiss GmbH
DISCO Pharmaceuticals
... programs in Small Cell Lung Cancer and Microsatellite-Stable Colorectal Cancer. Experienced team of ... programs in Small Cell Lung Cancer and Microsatellite-Stable Colorectal Cancer. Experienced team of ...
DISCO Pharmaceuticals – The surfaceome company
... development of novel therapeutics. Our initial discovery projects are on Small Cell Lung Cancer and ... patients. Roman has a particular interest in lung cancer and leads the worldwide largest research ... therapeutics. Our initial discovery projects are on Small Cell Lung Cancer and microsatellite-stable Colorectal ... interest in lung cancer and leads the worldwide largest research initiative on small cell lung cancer ...